Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2.
COVID-19
SARS-CoV-2
computational drug discovery
drug repurposing and molecular docking
molecular dynamics
virtual screening (VS)
Journal
Frontiers in chemistry
ISSN: 2296-2646
Titre abrégé: Front Chem
Pays: Switzerland
ID NLM: 101627988
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
08
2020
accepted:
13
11
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
The rapidly developing pandemic, known as coronavirus disease 2019 (COVID-19) and caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently spread across 213 countries and territories. This pandemic is a dire public health threat-particularly for those suffering from hypertension, cardiovascular diseases, pulmonary diseases, or diabetes; without approved treatments, it is likely to persist or recur. To facilitate the rapid discovery of inhibitors with clinical potential, we have applied ligand- and structure-based computational approaches to develop a virtual screening methodology that allows us to predict potential inhibitors. In this work, virtual screening was performed against two natural products databases, Super Natural II and Traditional Chinese Medicine. Additionally, we have used an integrated drug repurposing approach to computationally identify potential inhibitors of the main protease of SARS-CoV-2 in databases of drugs (both approved and withdrawn). Roughly 360,000 compounds were screened using various molecular fingerprints and molecular docking methods; of these, 80 docked compounds were evaluated in detail, and the 12 best hits from four datasets were further inspected
Identifiants
pubmed: 33425850
doi: 10.3389/fchem.2020.590263
pmc: PMC7786237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
590263Informations de copyright
Copyright © 2020 Abel, Paredes Ramos, Chen, Pérez-Sánchez, Coluzzi, Rocco, Marchetti, Mura, Simmaco, Bourne, Preissner and Banerjee.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer KV declared a past co-authorship with one of the authors HP-S to the handling Editor.
Références
Front Immunol. 2019 Mar 19;10:531
pubmed: 30941148
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
J Chem Inf Comput Sci. 2002 Nov-Dec;42(6):1273-80
pubmed: 12444722
J Chem Inf Model. 2013 Jan 28;53(1):201-9
pubmed: 23268595
Acta Physiol (Oxf). 2020 Jun;229(2):e13470
pubmed: 32220035
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
PLoS One. 2017 May 8;12(5):e0177371
pubmed: 28481922
J Med Chem. 1996 Aug 2;39(16):3049-59
pubmed: 8759626
Science. 2020 Mar 27;367(6485):1412-1413
pubmed: 32217705
Clin Pharmacol Drug Dev. 2018 Jun;7(5):474-483
pubmed: 28960888
Science. 2003 Jun 13;300(5626):1763-7
pubmed: 12746549
J Cheminform. 2009 Dec 17;1(1):20
pubmed: 20298522
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
PLoS One. 2011 Jan 06;6(1):e15939
pubmed: 21253603
Chin Med. 2019 May 23;14:21
pubmed: 31139247
Cell Mol Immunol. 2020 May;17(5):555-557
pubmed: 32235915
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
EBioMedicine. 2019 Apr;42:386-396
pubmed: 30905848
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):12997-13002
pubmed: 27799534
J Pain Res. 2020 May 26;13:1209-1222
pubmed: 32547183
P T. 2018 Oct;43(10):601-627
pubmed: 30271103
Front Biosci (Landmark Ed). 2018 Jan 1;23:997-1019
pubmed: 28930586
J Integr Med. 2020 Mar;18(2):152-158
pubmed: 32113846
Biochemistry. 2020 May 12;59(18):1769-1779
pubmed: 32293875
Sci Rep. 2020 Mar 2;10(1):3798
pubmed: 32123189
PLoS One. 2015 May 29;10(5):e0124878
pubmed: 26024233
Mol Inform. 2020 Aug;39(8):e2000028
pubmed: 32162456
J Chem Inf Model. 2010 May 24;50(5):742-54
pubmed: 20426451
J Chem Inf Model. 2020 Jun 22;60(6):3277-3286
pubmed: 32315171
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
Travel Med Infect Dis. 2020 Mar - Apr;34:101615
pubmed: 32145386
Br J Pharmacol. 2018 Jan;175(2):168-180
pubmed: 28369768
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
Acc Chem Res. 2000 Dec;33(12):889-97
pubmed: 11123888
Antimicrob Agents Chemother. 2018 Dec 21;63(1):
pubmed: 30397055
Sci Rep. 2017 Nov 17;7(1):15771
pubmed: 29150641
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Acta Otorhinolaryngol Ital. 2018 Apr;38(SUPPL. 1):S1-S106
pubmed: 29967548